The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. Zhu, R., Kiser, J. J., Seifart, H. I., Werely, C. J., Mitchell, C. D., D'Argenio, D. Z., & Fletcher, C. V. Journal of Clinical Pharmacology, 52(4):511--519, April, 2012. doi abstract bibtex The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled in a randomized, double-blind, controlled trial of isoniazid for prevention of tuberculosis disease and latent infection. Plasma concentration-time measurements of isoniazid from 151 infants (starting at 3-4 months of age) receiving isoniazid 10 to 20 mg/kg/d orally during the course of the 24-month study were incorporated in a population analysis along with NAT2 genotype, body weight, age, and sex. The results showed a different NAT2 enzyme maturation profile for each of the 3 acetylation groups, with the 70-kg body weight-normalized typical apparent clearance for the fast and intermediate acetylators increasing from 14.25 L/h and 10.88 L/h at 3 months of age to 22.84 L/h and 15.58 L/h at 24 months of age, respectively, with no significant change in the apparent clearance of the slow group during this period. A hypothesis is proposed to explain the genotype-dependent enzyme maturation processes for the NAT2 enzyme.
@article{ zhu_pharmacogenetics_2012,
title = {The pharmacogenetics of {NAT}2 enzyme maturation in perinatally {HIV} exposed infants receiving isoniazid},
volume = {52},
issn = {1552-4604},
doi = {10.1177/0091270011402826},
abstract = {The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled in a randomized, double-blind, controlled trial of isoniazid for prevention of tuberculosis disease and latent infection. Plasma concentration-time measurements of isoniazid from 151 infants (starting at 3-4 months of age) receiving isoniazid 10 to 20 mg/kg/d orally during the course of the 24-month study were incorporated in a population analysis along with NAT2 genotype, body weight, age, and sex. The results showed a different NAT2 enzyme maturation profile for each of the 3 acetylation groups, with the 70-kg body weight-normalized typical apparent clearance for the fast and intermediate acetylators increasing from 14.25 L/h and 10.88 L/h at 3 months of age to 22.84 L/h and 15.58 L/h at 24 months of age, respectively, with no significant change in the apparent clearance of the slow group during this period. A hypothesis is proposed to explain the genotype-dependent enzyme maturation processes for the NAT2 enzyme.},
language = {eng},
number = {4},
journal = {Journal of Clinical Pharmacology},
author = {Zhu, Rui and Kiser, Jennifer J. and Seifart, Heiner I. and Werely, Cedric J. and Mitchell, Charles D. and D'Argenio, David Z. and Fletcher, Courtney V.},
month = {April},
year = {2012},
pmid = {21558457},
pmcid = {PMC3182303},
keywords = {Administration, Oral, Age Factors, Antitubercular Agents, Arylamine N-Acetyltransferase, Child, Preschool, Dose-Response Relationship, Drug, Double-Blind Method, Female, Genotype, HIV Infections, Humans, Infant, Infectious Disease Transmission, Vertical, Isoniazid, Latent Tuberculosis, Male, Pharmacogenetics, Pregnancy, Pregnancy Complications, Infectious, Prospective Studies, South Africa, Tuberculosis},
pages = {511--519}
}
Downloads: 0
{"_id":"P5L7MPcGH8J6Q7BAK","bibbaseid":"zhu-kiser-seifart-werely-mitchell-dargenio-fletcher-thepharmacogeneticsofnat2enzymematurationinperinatallyhivexposedinfantsreceivingisoniazid-2012","downloads":0,"creationDate":"2015-06-25T09:01:23.285Z","title":"The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid","author_short":["Zhu, R.","Kiser, J.<nbsp>J.","Seifart, H.<nbsp>I.","Werely, C.<nbsp>J.","Mitchell, C.<nbsp>D.","D'Argenio, D.<nbsp>Z.","Fletcher, C.<nbsp>V."],"year":2012,"bibtype":"article","biburl":"https://api.zotero.org/users/559844/collections/2NP2XXNP/items?key=hqNfyop631uL1rdCcM8Pjttm&format=bibtex&limit=100","bibdata":{"abstract":"The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled in a randomized, double-blind, controlled trial of isoniazid for prevention of tuberculosis disease and latent infection. Plasma concentration-time measurements of isoniazid from 151 infants (starting at 3-4 months of age) receiving isoniazid 10 to 20 mg/kg/d orally during the course of the 24-month study were incorporated in a population analysis along with NAT2 genotype, body weight, age, and sex. The results showed a different NAT2 enzyme maturation profile for each of the 3 acetylation groups, with the 70-kg body weight-normalized typical apparent clearance for the fast and intermediate acetylators increasing from 14.25 L/h and 10.88 L/h at 3 months of age to 22.84 L/h and 15.58 L/h at 24 months of age, respectively, with no significant change in the apparent clearance of the slow group during this period. A hypothesis is proposed to explain the genotype-dependent enzyme maturation processes for the NAT2 enzyme.","author":["Zhu, Rui","Kiser, Jennifer J.","Seifart, Heiner I.","Werely, Cedric J.","Mitchell, Charles D.","D'Argenio, David Z.","Fletcher, Courtney V."],"author_short":["Zhu, R.","Kiser, J.<nbsp>J.","Seifart, H.<nbsp>I.","Werely, C.<nbsp>J.","Mitchell, C.<nbsp>D.","D'Argenio, D.<nbsp>Z.","Fletcher, C.<nbsp>V."],"bibtex":"@article{ zhu_pharmacogenetics_2012,\n title = {The pharmacogenetics of {NAT}2 enzyme maturation in perinatally {HIV} exposed infants receiving isoniazid},\n volume = {52},\n issn = {1552-4604},\n doi = {10.1177/0091270011402826},\n abstract = {The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled in a randomized, double-blind, controlled trial of isoniazid for prevention of tuberculosis disease and latent infection. Plasma concentration-time measurements of isoniazid from 151 infants (starting at 3-4 months of age) receiving isoniazid 10 to 20 mg/kg/d orally during the course of the 24-month study were incorporated in a population analysis along with NAT2 genotype, body weight, age, and sex. The results showed a different NAT2 enzyme maturation profile for each of the 3 acetylation groups, with the 70-kg body weight-normalized typical apparent clearance for the fast and intermediate acetylators increasing from 14.25 L/h and 10.88 L/h at 3 months of age to 22.84 L/h and 15.58 L/h at 24 months of age, respectively, with no significant change in the apparent clearance of the slow group during this period. A hypothesis is proposed to explain the genotype-dependent enzyme maturation processes for the NAT2 enzyme.},\n language = {eng},\n number = {4},\n journal = {Journal of Clinical Pharmacology},\n author = {Zhu, Rui and Kiser, Jennifer J. and Seifart, Heiner I. and Werely, Cedric J. and Mitchell, Charles D. and D'Argenio, David Z. and Fletcher, Courtney V.},\n month = {April},\n year = {2012},\n pmid = {21558457},\n pmcid = {PMC3182303},\n keywords = {Administration, Oral, Age Factors, Antitubercular Agents, Arylamine N-Acetyltransferase, Child, Preschool, Dose-Response Relationship, Drug, Double-Blind Method, Female, Genotype, HIV Infections, Humans, Infant, Infectious Disease Transmission, Vertical, Isoniazid, Latent Tuberculosis, Male, Pharmacogenetics, Pregnancy, Pregnancy Complications, Infectious, Prospective Studies, South Africa, Tuberculosis},\n pages = {511--519}\n}","bibtype":"article","doi":"10.1177/0091270011402826","id":"zhu_pharmacogenetics_2012","issn":"1552-4604","journal":"Journal of Clinical Pharmacology","key":"zhu_pharmacogenetics_2012","keywords":"Administration, Oral, Age Factors, Antitubercular Agents, Arylamine N-Acetyltransferase, Child, Preschool, Dose-Response Relationship, Drug, Double-Blind Method, Female, Genotype, HIV Infections, Humans, Infant, Infectious Disease Transmission, Vertical, Isoniazid, Latent Tuberculosis, Male, Pharmacogenetics, Pregnancy, Pregnancy Complications, Infectious, Prospective Studies, South Africa, Tuberculosis","language":"eng","month":"April","number":"4","pages":"511--519","pmcid":"PMC3182303","pmid":"21558457","title":"The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid","type":"article","volume":"52","year":"2012","bibbaseid":"zhu-kiser-seifart-werely-mitchell-dargenio-fletcher-thepharmacogeneticsofnat2enzymematurationinperinatallyhivexposedinfantsreceivingisoniazid-2012","role":"author","urls":{},"keyword":["Administration","Oral","Age Factors","Antitubercular Agents","Arylamine N-Acetyltransferase","Child","Preschool","Dose-Response Relationship","Drug","Double-Blind Method","Female","Genotype","HIV Infections","Humans","Infant","Infectious Disease Transmission","Vertical","Isoniazid","Latent Tuberculosis","Male","Pharmacogenetics","Pregnancy","Pregnancy Complications","Infectious","Prospective Studies","South Africa","Tuberculosis"],"downloads":0},"search_terms":["pharmacogenetics","nat2","enzyme","maturation","perinatally","hiv","exposed","infants","receiving","isoniazid","zhu","kiser","seifart","werely","mitchell","d'argenio","fletcher"],"keywords":["administration","oral","age factors","antitubercular agents","arylamine n-acetyltransferase","child","preschool","dose-response relationship","drug","double-blind method","female","genotype","hiv infections","humans","infant","infectious disease transmission","vertical","isoniazid","latent tuberculosis","male","pharmacogenetics","pregnancy","pregnancy complications","infectious","prospective studies","south africa","tuberculosis"],"authorIDs":[],"dataSources":["vtFqZHBhXLQtCKytZ"]}